La société n’a malheureusement pas amélioré sa communication sur la politique de rémunération 2019 des dirigeants. Si le fait que les dirigeants sociaux ne soient pas rémunérés au titre de leur mandats sociaux, mais au titre d'un contrat de travail au sein de la société est sans doute la raison pour laquelle la société ne communique pas suffisamment d'information sur cette politique de rémunération 2019, il n’en demeure pas moins que cela ne respecte pas complètement l'esprit de la loi Sapin II, ce que nous regrettons.
De la même façon, on regrettera le manque de communication de la société sur les rémunérations variables attribuées au titre de l’exercice. En effet, celles-ci sont composées à la fois d’une prime d'intéressement et d’une prime sur objectif mais aucune information sur les modalités sous-jacentes d’attribution de ces primes n’est communiquée, ce qui ne permet pas aux actionnaires de comprendre comment sont déterminés les montants attribués.
AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.